Skip to content

Cancer Health Center

Font Size

FDA: Prostate Cancer Drugs Raise Diabetes, Heart Risk

New Warnings for Eligard, Lupron, Trelstar, Viadur, Zoladex
WebMD Health News
Reviewed by Laura J. Martin, MD

Oct. 20, 2010 -- A class of drugs used to treat advanced prostate cancer raises patients' risk of diabetes, heart disease, and stroke, the FDA today warned.

The five drugs, gonadotropin-releasing hormone (GnRH) agonists, are approved for the treatment of advanced prostate cancer. They are:

All of the drugs will stay on the market but will be required to carry new label warnings.

The risk that the drugs will trigger diabetes or heart disease/stroke appear small, the FDA says. But recent studies suggest that doctors should monitor blood sugar levels and watch for signs of heart disease in men taking these drugs.

Patients should not stop taking these drugs, but should discuss any concerns with their doctors.

Before beginning treatment with any of these drugs, patients should tell their doctors whether they've ever had diabetes, heart disease, a heart attack, or a stroke. They should also report any history of high blood pressure, high cholesterol, or cigarette smoking.

Today's FDA action follows the agency's announcement last May that it was reviewing safety concerns raised by new data on GnRH agonists.

Today on WebMD

Colorectal cancer cells
New! I AM Not Cancer Facebook Group
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Real Cancer Perspectives
Jennifer Goodman Linn self-portrait
what is your cancer risk
colorectal cancer treatment advances
breast cancer overview slideshow
prostate cancer overview
lung cancer overview slideshow
ovarian cancer overview slideshow
Actor Michael Douglas